Nerve Growth Factor Shows Promise in Treating Traumatic Brain Injury in Children

Strategic Insights -

Traumatic brain injury and hypoxic-ischemic encephalopathy are major causes of long-term neurological disability in children, with limited options for effective neuronal recovery. Recent research has highlighted the therapeutic potential of nerve growth factor (NGF) in promoting neural repair through mechanisms such as neuroprotection, neurogenesis, and the modulation of neuroinflammation. A comprehensive review of 17 studies has found that NGF administration reduces neuroinflammation, enhances neurogenesis, and supports neuronal survival following traumatic brain injury and hypoxic-ischemic encephalopathy.

Key Takeaways:

  • NGF demonstrates significant promise as a neuroprotective and neuroregenerative agent in pediatric brain injury, with both experimental and early clinical evidence supporting its safety and efficacy.
  • Seventeen studies met the inclusion criteria, encompassing both preclinical and clinical research, which consistently demonstrated that NGF administration reduces neuroinflammation, enhances neurogenesis, and supports neuronal survival following traumatic brain injury and hypoxic-ischemic encephalopathy.
  • Clinical studies, including case reports of pediatric patients treated with intranasal NGF, reported improvements in motor and cognitive function, neuroimaging findings, and electrophysiological parameters, with no significant adverse effects observed.
  • Preclinical models consistently demonstrated that NGF administration reduces neuroinflammation, enhances neurogenesis, and supports neuronal survival following traumatic brain injury and hypoxic-ischemic encephalopathy.
  • Large-scale controlled clinical trials are warranted to validate the preliminary findings and to determine the optimal dosage regimens and administration schedules for NGF in the treatment of traumatic brain injury and hypoxic-ischemic encephalopathy.
  • The therapeutic potential of NGF in promoting neural repair through mechanisms such as neuroprotection, neurogenesis, and the modulation of neuroinflammation.

Statistics:

  • Only 17 studies met the inclusion criteria, encompassing both preclinical and clinical research.
  • 13 of the 17 studies were preclinical, demonstrating that NGF administration reduces neuroinflammation, enhances neurogenesis, and supports neuronal survival following traumatic brain injury and hypoxic-ischemic encephalopathy.
  • 4 of the 17 studies were clinical, including case reports of pediatric patients treated with intranasal NGF, which reported improvements in motor and cognitive function, neuroimaging findings, and electrophysiological parameters.

Sources:

  • Nerve Growth Factor in Pediatric Brain Injury: From Bench to Bedside. Pharmaceuticals, 2025, 18(6):929.
  • NewsRx. Research from Institute for Cancer Research and Treatment (IRCCS) Broadens Understanding of Traumatic Brain Injury (Nerve Growth Factor in Pediatric Brain Injury: From Bench to Bedside). Health & Medicine Week. July 11, 2025; p 5189.